Endocrine late sequelae in long-term survivors of childhood non ...

original article
Table 1. Baseline characteristics of NHL survivors
NHL survivors Non-B-NHL B-NHL + LCAL
N (male/female) 84 (62/22) 32 (22/10) 52 (40/12)
Age at follow-up (years) a
21 (9–40) 23 (9–37) 20 (10–40)
Age at diagnosis (years) a
8 (2–16) 8 (2–16) 8 (2–16)
Duration of treatment
13 (1–38) 24 (4–38) 6 (1–28)
(months) a
Follow-up time (years) a
Specification of
12 (4–30) 14 (4–25) 9 (5–30)
chemotherapy n (%) TCD (mg/m 2 ) n (%) TCD (mg/m 2 ) n (%) TCD (mg/m 2 )
Methotrexate 79 (94) 15 000 (1500–30 000) 31 (97) 6900 (1500–20 000) 48 (92) 15 000 (1500–30 000)
Vincristine 78 (93) 11 (2–141) 32 (100) 18 (7–141) 46 (88) 9 (2–25)
Cytarabine 76 (90) 1800 (1000–42 500) 28 (88) 3000 (1200–9800) 45 (87) 1800 (1000–42 500)
Corticosteroids b
71 (85) 3413 (710–28 670) 30 (94) 4407 (1840–26 490) 39 (75) 1418 (700–28 670)
Anthracyclines 65 (77) 180 (60–480) 29 (91) 280 (160–480) 36 (69) 180 (60–480)
Cyclophosphamide 69 (82) 5500 (360–16 200) 18 (56) 3000 (2000–6000) 51 (98) 5800 (360–16 200)
Ifosfamide 9 (11) 12 000 (4000–16 000) 1 (3) 4000 (NA) 8 (15) 120 000 (6000–16 000)
Busulfan 1 (1) 480 (NA) 0 NA 1 (2) 480 (NA)
Melphalan 1 (1) 140 (NA) 0 NA 1 (2) 140 (NA)
a Median (range).
b TCD prednisone plus TCD dexamethasone (dexamethasone was converted to prednisone using factor 6.67).
NHL, non-Hodgkin lymphoma; LCAL, large-cell anaplastic lymphoma; TCD, total cumulative doses; NA, not applicable.
anthropometry
Height was measured using a Harpenden stadiometer and compared with
Dutch normative values [33]. Height of survivors of other ethnicities
was compared with normative values for these ethnicities [34, 35]. No data
on target height were available. Weight was measured on a standard clinical
balance. Body mass index (BMI) was calculated as weight (kg)/[height
(m)] 2 . BMI of survivors